PCN39 Economic Impact of Denosumab for Skeletal Related Event Prevention in Patients with Prostate Cancer and Bone Metastasis from a United State Managed Care Organization Perspective  by Arellano, J. et al.
A398  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
medium risk (OS mean time = 11.6 months, 61%) and other of low risk were obtained 
(OS mean time = 31.7 months, 38%). For NSCLC patients with immunotherapy a 
population of medium risk (OS mean time = 11.2 months, 55%); a population of 
low risk (OS mean time = 23.8 months, 33%); and another of very low risk or long-
term survival were obtained (OS mean time = 55.5 months, 12%). ConClusions: 
Our analyses support the existence of several populations regarding OS among 
advanced stage lung cancer.
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Survival aNalySiS uSed iN ComPaNy SubmiSSioNS to the NatioNal 
CeNtre for PharmaCoeCoNomiCS, irelaNd
McCullagh L., Barry M.
National Centre for Pharmacoeconomics, Dublin, Ireland
objeCtives: Many company submissions received by Health Technology 
Assessment (HTA) Agencies evaluate the cost effectiveness of interventions which 
impact on survival. An accurate estimate of the survival benefit is required to cal-
culate a reliable estimate of cost effectiveness. Generally the relevant trial data 
is immature and must be extrapolated. Many extrapolation models are available. 
Model choice is critical; different models can lead to different cost effectiveness 
results. The objectives were to review the methods/justification of the survival anal-
ysis used in company submissions to the National Centre for Pharmacoeconomics 
(NCPE). A further aim was to develop NCPE Guidance for the future handling of 
survival analysis. Methods: Relevant submissions to the NCPE (economic evalu-
ations which had dealt with advanced and/or metastatic cancer) were reviewed 
to determine the methods/justification of the survival analysis used. Results: 
Twelve submissions were evaluated. Appropriately, the mean overall survival (OS) 
had been estimated and used in eight cases (67%). Median OS estimates had been 
estimated/used in three (25%). It was unclear which measure had been used in the 
remaining submission. The submissions which had used mean OS estimates were 
further investigated. Parametric model-based extrapolation techniques had been 
used to calculate the mean estimates in all eight. The most popular parametric 
models were the Weibull (n= 3) and the loglogistic (n= 3). The methods used to fit the 
parametric models varied. Most commonly the model was fitted using individual 
patient-level data. Some justification for the choice of extrapolation technique was 
offered in five submissions; AIC +/or BIC were estimated in three and visual inspec-
tion was reported in two. ConClusions: Survival analysis has not been conducted 
appropriately in all HTAs. Justification of the choice of model is not always offered. 
Moving forward, NCPE Guidance is required to ensure that survival analysis using 
patient-level data is conducted appropriately. These will be presented.
CaNCer – Cost Studies
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budget imPaCt of metaStatiC CaStrate-reSiStaNt ProState CaNCer 
(CrPC) to germaN PayerS
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1PriceSpective LLC, Cambridge, MA, USA, 2Teva, Inc, Horsham, PA, USA
objeCtives: The 2010 Urological Association Guidelines for Management of 
Castrate-Resistant Prostate Cancer (CRPC) recommend docetaxel plus prednisone 
for first-line chemotherapy for symptomatic metastatic CRPC patients who have 
progressed from hormone therapy. Since 2010, several CRPC agents with better toler-
ability and longer survival have launched. These improved therapies are causing a 
shift in practice. The aim of our analysis was to 1) quantify the 3-year mCRPC budget 
impact for the German health system based on the practice shift, and 2) estimate 
the cost per additional month of progression-free survival (PFS). Methods: A con-
ceptual decision analytic model was developed for the German health system to 
estimate the impact on direct medical costs of a therapy shift in CRPC over three 
years. Guideline recommended regimens were represented in model with three 
lines of therapies: palliative, abiraterone, enzalutamide, docetaxel and cabazitaxel. 
Progression in therapy was measured as the duration of PFS. A targeted literature 
search identified US per-patient-per-month costs of docetaxel treated patients (hos-
pitalization= € 954, ambulatory= € 765, ER= € 32, MD= € 318) and were adapted to the 
German health system by applying a published purchase price parity factor. Drug 
costs were based on Ex-factory pricing. Adverse event rates were used as a proxy 
to derive relative resource utilization of other treatments. Utilization of CRPC regi-
mens was informed by interviews with EU opinion leaders. Results: The shift in 
practice pattern is expected to increase the German health system’s 3-year budget 
by € 23 million. The additional cost/month of PFS is estimated to decrease by € 99/
month from € 4,659 for current treatment mix to € 4,560 for future treatment mix 
by year 3. ConClusions: From the German health system’s perspective, a change 
in practice pattern will result in an increase in total budget of € 23 million. The 
reduction in cost/month of PFS of € 99/month indicates the shift in practice will 
use more efficient therapies.
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eCoNomiC imPaCt of deNoSumab for Skeletal related eveNt 
PreveNtioN iN PatieNtS with ProState CaNCer aNd boNe metaStaSiS 
from a uNited State maNaged Care orgaNizatioN PerSPeCtive
Arellano J.1, Cristino J.2, Chen K.3
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objeCtives: To evaluate clinical and economic impact of increasing deno-
sumab use compared to zoledronic acid (ZA) in PrCa patients with BM to a 
MCO. Methods: An economic model was developed to estimate clinical and eco-
nomic impact to a 1-million-member US MCO of introducing denosumab as bone 
targeting agent (BTA) for prevention of SREs in PrCa patients with BM. Total number 
of patients receiving BTA was estimated based on disease prevalence and treat-
ment eligibility in this population. The real-world SRE rates in ZA-treated patients 
were derived from a large commercial database and used together with the trial-
(66.0%) AF patients and 406 (66.1%) PF patients were classified in “better responders” 
subgroup. Lognormal and loglogistic distributions were the 2 distributions provid-
ing the best fit to the observed OS data, with very similar and good fit. Mean OS 
over 15-years using loglogistic distribution was 24.8 vs. 18.6 months for AF and PF, 
respectively. ConClusions: Post-hoc analysis suggested that the “better respond-
ers” subgroup of patients within VELOUR derived enhanced survival benefit with 
the AF combination. The results highlight the therapeutic benefit of AF in clinically 
relevant patient subpopulations.
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faCtorS driviNg iNequality iN ProState CaNCer Survival: a 
PoPulatioN baSed Study
Burns R.1, Sharp L.2, Sullivan F.J.3, Deady S.2, Drummond F.J.2, O’Neill C.1
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objeCtives: As cancer control strategies have become more successful, issues 
around survivorship have become increasingly important to researchers and policy 
makers. The aim of this study was to examine the role of a range of clinical and 
socio-demographic variables in explaining variations in survival after prostate 
cancer diagnosis, paying particular attention to the role of health care provider(s) 
(i.e. private vs. public) and socio-economic status. Methods: Data were extracted 
from the National Cancer Registry Ireland, for patients diagnosed with prostate 
cancer from 1998-2009 (N= 26,183). A series of multivariate Cox and logistic regres-
sion models were used to examine the role of health care provider and socio-
economic status (area-based deprivation) on survival, controlling for age, stage, 
Gleason grade, marital status and region. Survival was based on all-cause mortal-
ity. Results: Individuals who were treated in a private care setting were more 
likely to have survived than those who had not, when other factors were controlled 
for. A socio-economic gradient was evident with respect to marital status, region 
of residence, clinical stage and Gleason grade. The effect of socio-economic status 
was modified by health care provider, such that risk of death was higher in those 
of lower socio-economic status for men treated by public, but not private, provid-
ers. ConClusions: The role of health care provider (a proxy for voluntary private 
insurance) and socio-economic status in survival of men with prostate cancer may 
give rise to equity concerns regarding the operation of the Irish health care system 
and warrants further investigation.
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PatieNtS treated with iPilimumab: model baSed aNalySiS
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objeCtives: There are few treatments available for advanced melanoma and sur-
vival rates are low. While the incidence of the disease continues to rise, only two 
new treatments have come to the market recently: ipilimumab and vemurafenib. 
Ipilimumab is indicated in Europe for the treatment of advanced melanoma in 
adults who have received prior therapy. Ipilimumab has demonstrated a statistically 
significant improvement in overall survival in 2 Phase III RCTs. Prolonged survival 
(> 2 years in some patients) has been shown (MDX020 & 024). Methods: Data from 
the MDX010-20 trial, which was conducted in previously treated patients with a 
maximum follow up duration of 55 months, was used to develop an economic model 
for health technology assessment in England & Wales. This model has been used 
to predict the conditional survival (CS) of patients treated with ipilimumab (based 
on both ipilimumab containing arms) compared to gp100 – the active control. The 
model used patient level Kaplan–Meier data for the first 18 months, parametric 
curves fitted to the patient level data from 18 months to 5 years, and published AJCC 
registry data beyond 5 years. Results: The curves were a good fit to the MDX010-20 
trial data (MAE 0.003) and consistent with published Phase II data (which provides 
a longer time horizon). Given an ipilimumab patient has survived 2 years, the mod-
elled probability of being alive at 5 years is 67% (49%,79%) (gp100: 15% [9%,21%]) and 
at 10 years is 54% (39%, 63%) (gp100: 2% [1%,3%]). ConClusions: The model shows 
that a substantial proportion of patients treated with ipilimumab surviving to 2 
years are likely to have sustained survival benefits: more than 50% of ipilimumab 
patients surviving to 2 years are alive at 10 years, with 29% remaining alive at 20 
years. This level of sustained survival is not shown by gp100 patients.
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eStimatiNg aNd modeliNg loNg term Survival iN luNg CaNCer uSiNg 
mixture ParametriC modelS
Sánchez L.1, Luaces P.1, Viada C.1, Galan Y.2, Ballesteros J.3, Rodríguez P.C.1, Crombet T.1,  
Lage A.1
1Center of Molecular Immunology, Havana, Cuba, 2Cuban National Cancer Registry, Havana, 
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objeCtives: To ascertain the existence of several populations regarding overall sur-
vival (OS) in patients with advanced non-small-cell lung cancer (NSCLC). Methods: 
Data of OS from the Cuban National Cancer Registry (CNCR) and from Cuban mul-
ticentre trials of immunotherapy were analysed with a lognormal mixed model 
assuming 1 to 6 underlying populations. The Bayesian Information Criterion (BIC) 
was used to select the best model fitted to the data in all cases. Results: The CNCR 
provided data for 31133 patients diagnosed with lung cancer since January 1998 
until December 2008. Of those, 7286 patients presented stages IIIb-IV of NSCLC at 
diagnosis and were selected for analysis. The immunotherapy Cuban trials provided 
data for more than 750 patients enrolled in 8 trials conducted since 1997 until 2010. 
The mixed model applied to CNCR data separated 4 populations: very high risk (OS 
mean time = 0.62 months, 23% of the sample); high risk (OS mean time = 3.1 months, 
34%); medium risk (OS mean time = 9.2 months, 35%); and low risk (OS mean time 
= 29.1 months, 8%). Results for clinical trials separated 2 populations for controls 
and 3 populations for the immunotherapy groups. For controls a population of 
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objeCtives: Whilst the cost-effectiveness of everolimus + exemestane (EVE+EXE) 
versus placebo + exemestane (PBO+EXE) in patients with ER+ HER2- metastatic 
breast cancer has been demonstrated elsewhere, this is the first analysis to assess 
the implications for health spending at a population level. Methods: The model 
uses a cumulative cohort approach, allowing incident patients to enter the model 
each year over a five-year period. The incident population was based on several 
factors: (i) the female population aged > 15 years; (ii) the proportion of those women 
with advanced invasive breast cancer; (iii) the proportion who are post-menopausal; 
(iv) the proportion who are hormone receptor positive; (v) the proportion who are 
HER2-; (vi) the proportion with asymptomatic visceral disease, and (vii) the propor-
tion for whom hormonal therapy is appropriate. Finally, the cohort was filtered 
to show those who had previously relapsed or progressed on NSAI. ‘Per patient’ 
treatment and adverse event costs were generated based on treatment-specific 
progression-free survival curves, and multiplied by the number of patients expected 
to receive each treatment according to market share data and likely uptake rates. 
An incremental analysis was performed, where two scenarios were compared: (i) a 
world without EVE+EXE, and (ii) a world with EVE+EXE. Results: It is expected that 
a total of 1,052 patients will be eligible to receive EVE+EXE over a five-year period. 
In a ‘world without EVE+EXE’, the total five year cost was estimated as £1,652,904. 
Assuming an annual uptake rate of 10%, in a ‘world with EVE+EXE’ the total cost 
over the same period was expected to be £2,271,606. Therefore, the incremental cost 
associated with the introduction of EVE+EXE in England and Wales is £618,702 over 
five years. ConClusions: EVE+EXE was associated with modest increased health 
care costs but has, separately, been demonstrated to lead to incremental health 
benefits compared with other treatments.
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iNCorPoratiNg Stakeholder iNPut iNto budget imPaCt modelS to 
ComPare Stem Cell mobilizatioN StrategieS
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objeCtives: There is a dearth of published health economic evidence on stem cell 
(SC) mobilization that can be leveraged effectively for transplant center decision 
making. Our objective was to develop representative budget impact models (BIM) for 
key decision makers to estimate the total financial impact of adopting plerixafor for 
SC mobilization patients undergoing autologous peripheral stem cell transplanta-
tion (ASCT) for multiple myeloma and lymphoma. The BIMs were developed for EU5 
(France, Germany, Italy, Spain, UK) and United States (US). Methods: Prior to BIM 
development, in-depth interviews were conducted in EU5 (n= 33) and US (n= 20), to 
determine the most influential decison maker(s) for choosing a mobilization regi-
men. The choice of inputs and outputs that are critical for the adoption of plerixafor 
at the hospital level, were determined. Additionally, the BIM was developed using 
inputs from published literature and market research. Results: Primary research 
revealed that the center director and treating physician are the most influential 
decision makers, while hospital administrators, transplant coordinators, pharmacy 
directors, and apheresis directors have a more limited role. There was consensus 
on inputs critical for assessment: clinical (drug/regimen utilization, apheresis days, 
and success/failure rates) and economic (mobilization costs; drug costs; apheresis 
cost and hospitalization costs). Model outputs include: first mobilization success 
and total mobilization budget impact. Interviews with clinical experts, and primary 
literature review determined that the relevant mobilization regimen comparators 
for the models are Granulocyte-Colony Stimulating Factor (G-CSF) alone, G-CSF and 
plerixafor, G-CSF and chemotherapy mobilization with cyclophosphamide and the 
triple regimen G-CSF, chemotherapy mobilization and plerixafor. ConClusions: 
Conducting primary interviews with key stakeholders and using the latest clinical 
practice information for critical inputs/outputs is essential for developing a repre-
sentative model that is applicable to decison makers.
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breaSt CaNCer SCreeNiNg Program iN the baSque CouNtry: CoStS aNd 
health beNefitS aSSeSSmeNt through diSCrete eveNt SimulatioN
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objeCtives: In the Basque Country (Spain), mammographies have been done in bien-
nial basis to women in their fifties and sixties since 1996. The main objective of this 
project was the evaluation of the impact of the Screening program in terms of costs 
and health in the Basque women population since 1996. Methods: A discrete event 
simulation model was built to represent the natural history of breast cancer in women 
invited to the breast cancer screening program in the Basque Country. The disease 
progress was described in three main states (healthy, preclinical and clinical) in the 
model. We assumed all women would be diagnosed at the beginning of the clinical 
stage unless it had been diagnosed previously through the screening program. The data 
collected among the 15 years when the screening program was held allowed model’s 
validation. In order to compare the economic impact of these scenarios mammography 
and treatment costs – depending on the diseasestage at diagnosis – were included. The 
health impact assessment was based on quality adjusted life expectancy of cancer 
patients. Results: Since the screening program started working, 8,925 cancers were 
detected among 313,475 women who attended the screening which represents the 76% 
of the invited ones. 60% of the diagnosed cancers were detected through the screening 
program. All the mammographies carried out during the evaluated years costed 46 
million Euros. Each cancer detected in the screened scenario costs 29,581.06€ , in the 
based treatment effect for denosumab versus ZA to estimate the denosumab SRE 
rate. Total number of SREs, total SRE management medical cost, BTA drug cost, 
and total cost were calculated. The impact of denosumab per-member-per-month 
(PMPM) at increasing utilization rates was assessed by comparing to a scenario 
without denosumab, i.e., all patients received ZA and reported. Additionally, 
impact of annual increase in denosumab use was conducted. Results: A total 
of 63 PrCa patients with BM received BTA. In the scenario where all eligible patients 
receiving ZA, an annual total number of SREs was 120. An annual denosumab use 
of 20%, 35% or 45% resulted in 4.2%, 7.4%, and 9.5% reduction in total SREs and 
5.3%, 9.3%, and 11.9% reduction in medical costs of managing SREs, compared to 
all patients receiving ZA. The drug cost was partially offset by the reductions in 
the medical cost and the increase in total cost was minimal (1.2%-2.7%). The PMPM 
ranged $0.002-$0.005. Consecutive-year analysis showed $0.001 increase in PMPM 
with 10% denosumab utilization increase. ConClusions: Due to superior efficacy 
of denosumab versus ZA in SRE prevention in PrCa patients with BM, increased 
denosumab use results in medical cost reduction in a US MCO. Overall, denosumab 
provides additional clinical value with limited budget impact.
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objeCtives: Ipilimumab is the first drug to be licensed in Italy for the treatment 
of advanced melanoma in adults who have received prior therapy. This study 
aims to estimate the budget impact of ipilimumab in patients who live in the 
Veneto Region. Methods: Our analysis was performed from the perspective 
of the Italian health care system. Two scenarios were analyzed: one with the 
optimization of vials and the other without. Only drug acquisition costs (meas-
ured in euro) were considered into the analysis. All costs were referred to year 
2013. Results: Based on the incidence and mortality rates of the last three 
years, a total of 80 adult patients were assumed to be elegible for the treatment 
in the Veneto Region. The cost per mg of ipilimumab was € 53,70: one 10 ml vial 
contains 50 mg of ipilimumab and one 40 ml vial contains 200 mg of ipilimumab. 
The recommended induction regimen is 3 mg/kg administered intravenously 
every 3 weeks for a total of 4 doses. The costs per patient of one year’s therapy 
with ipilimumab ranged from € 45.108 with vial optimization (considering 4-5 
patients infused at the same time - average weight 70 kg) to € 53.700 without. 
The Veneto Region identified a single center for the preparation/administration 
of treatment to minimize drug waste and to reduce the yearly treatment cost 
per patient, with a saving of € 8.592 per patient/year. Applied to whole elegible 
patients (average weight 70-75 kg), it allows to obtain savings up to € 430.000-
690.000 per year. ConClusions: High prices for new cancer drugs are a growing 
concern to payers, given the large number of cancer drugs in development and 
the limited health care resources. Vial optimization may be an useful strategy 
to decrease waste, maximizing the use of health care resources and ensuring 
that eligible patients are treated.
PCN41
eCoNomiC evaluatioN of ePoetiN alfa hexal (biNoCrit) ComPared 
to darbePoetiN alfa (araNeSP) iN the treatmeNt of ChemotheraPy 
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objeCtives: To compare the budget requirements of utilizing epoetin alfa Hexal vs. 
darbepoetin alfa in the German health care system Methods: Anemia is a com-
mon side effect observed in patients receiving myelosuppressive chemotherapy. The 
purpose of this pharmacoeconomic analysis was to evaluate the cost-effectiveness 
of the short-acting biosimilar ESAs epoetin-alfa Hexal (EA) 30,000 or 40,000 IU weekly 
(QW) versus long-acting erythropoiesis-stimulating agent (ESA) darbepoetin alfa 
(DA) 150 mcg weekly (QW) and 500 mcg once every 3 weeks (Q3W) for the treatment 
of CIA. A budget impact model was constructed employing a payer perspective, per 
patient plus 5 year time horizon. The treatment period considered was based on 12 
weeks and was aligned with routine chemotherapy regimen administration. Model 
inputs included: medical treatment, outcomes, and health care service utilization 
from published clinical studies and summary of product characteristics recom-
mendation. Effectiveness of therapeutic alternatives was determined by comparing 
hemoglobin maintenance rates. Initial treatment with biosimilar epoetin α 30,000 
IU or 40,000 IU per week has been shown to produce a similar Hb response. Costs 
included only drug acquisition costs and reflect 2013 data. The analysis was per-
formed from the perspective of the German health care system. Results: The 
average expected pharmaceutical costs per patient were € 4,843 for DA Q3W, € 4,383 
for DA QW and € 2,944 for EA 30,000IU QW, € 3,946 for EA 40,000IU QW. Cost-savings 
associated utilizing with utilizing Epoetin Alfa Hexal 30-40,000 are 11-49% to DA 
QW and were 23-64% relative to DA 3QW. ConClusions: In the treatment of CIA 
among cancer patients in Germany, epoetin alfa Hexal is projected to provide more 
efficient use of health care resources compared to alternative treatment strategies 
with darbepoetin alfa.
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